Bencyclane as an anti-sickling agent

Kocak R., Baslamisli F., Guvenc B., Tamer L., Aikimbaev K., Isbir T.

BRITISH JOURNAL OF HAEMATOLOGY, cilt.92, sa.2, ss.329-331, 1996 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 92 Sayı: 2
  • Basım Tarihi: 1996
  • Doi Numarası: 10.1046/j.1365-2141.1996.d01-1466.x
  • Dergi Adı: BRITISH JOURNAL OF HAEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.329-331
  • Çukurova Üniversitesi Adresli: Evet

Özet

A vasodilating Ca2+ channel blocker, bencyclane, was used in 18 patients with homozygous sickle cell anaemia (SCD) to test the possible anti-sickling effect. With bencylane intervention the Na+-K+ ATPase activity increased from 256 +/- 29 to 331 +/- 37 nmolPi/mg protein/h (P < 0.0001) and the Ca2+-Mg2+ ATPase level increased from 172 +/- 12 to 222 +/- 44 nmolPi/mg protein/h (P < 0.0001). The intracytoplasmic Ca2+ concentration reduced from 3.5 +/- 0.6 to 2.7 +/- 0.25 mu mol/l (P < 0.0001). The patient's blood contained fewer irreversibly sickled cells (ISCs) (a reduction from 21.4% to 14.4%) (P < 0.05). At the same time MCHC of the erythrocytes decreased from 34.5 to 33.0 g/dl (P < 0.05). Bencyclane appears to be a promising anti-sickling agent that can be used orally in SCD.